# A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC

> **NCT07178171** · PHASE1 · RECRUITING · sponsor: **Xijing Hospital** · enrollment: 30 (estimated)

## Conditions studied

- TNBC, Triple Negative Breast Cancer

## Interventions

- **DRUG:** QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
- **DRUG:** Pirarubicin
- **DRUG:** Nab-paclitaxel
- **DRUG:** Carboplatin (AUC 5)
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT07178171
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-06
- **Primary completion:** 2027-08-01
- **Final completion:** 2030-08-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-11-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07178171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07178171, "A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07178171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*